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aME relationship between the release of platelet activating
factor (PAF), leukotriene C4/D4/E. (LTC4/D4/E) and
prostaglandin D (PGD2) from nasal mucosa in vtvo was
examined in 24 rhinitis patients allergic to the house dust
mite (HDM). During a double blind placebo controlled
cross-over study 200 lig fluticasone propionate aqueous
nasal spray (FPANS) was administered twice daily for two
weeks. In response to allergen provocation (100, 1 000,
10000 Bu/ml) and during the 9.5 h after this challenge
the nasal fluid was obtained by washing the nose with
saline and the levels of PAF, LTC/D/E and PGD2, as
indicators of mediator release, were measured at the fol-
lowing time-points: baseline (t 1/2), allergen provoca-
tion with 10 000 Bu/ml (t 0), 3.5 and 7.5 h (late phase).
After allergen provocation the levels of the mediators
increased in the nasal fluids of placebo treated patients
(x-fold increase to baseline: PAF, 15; LTC/D4/E, 12;
PGD2, 1.5). In fluids of patients treated with FPANS these
levels tended to decrease. At the time of provocation the
levels of PAF, LTC/D/E and PGD showed a significant
correlation. The results indicate that these mediators can
be used as markers of allergic reactions against house
dust mites and that fluticasone propionate aqueous nasal
spray tended to reduce the release ofmediators ofinflam-
mation correlated with beneficial effects on clinical
symptoms in this type of allergic reactions.
Key words: Eicosanoids, Fluticasone propionate aqueous
nasal spray, House dust mite, Platelet activating factor
Effect of fluticasone propionate
aqueous nasal spray treatment on
platelet activating factor and
eicosanoid production by nasal
mucosa in patients with a house
dust mite allergy
I. M. Garrelds,1,a,cA T. de Graaf-in ’t Veld,a
A. P. H. Jansen, R. Gerth van Wijkfl
and F.J. Zijlstra
Department of Pharmacology, Faculty of
Medicine, Erasmus University Rotterdam; and
Department of Allergology, University Hospital




In the 1920s house dust allergy was recognized
when dust extracts from mattresses and vacuum
cleaners were found to give relevant positive reac-
tions in skin test on asthmatics. 1," Since 1964 it has
been known that the majority of house dust sensitive
patients show positive skin reactions to the mites of
the genus Dermatophagoides farinae (Df) and D.
pteronyssinus (Dp) as a major source in house dust.
The faeces particles, in particular, contain allergenic
material in a concentrated form. Practicable control
measures, such as chemicals, cleaning, ventilation
and temperature regulation have only been able to
reduce the number of mites in houses to some extent
but the clinical effect has been disappointing.1, As
long as these methods are insufficient other forms of
therapy are needed, such as immuno-therapy and
symptomatic medication.7-1
House dust mites are the major cause of perennial
rhinitis. The pathophysiology of allergic rhinitis,
however, has been mainly studied in pollen allergy.
Nasal challenges and lavages were performed at
the Department of Allergology and the measurements of
platelet activating factor and eicosanoids at the Department of
Pharmacology
Naclerio et al.
11 developed a model to explore the
role of inflammatory mediators in ragweed
pollinosis. As a consequence of cross-linking of IgE
on mast cells and basophils by antigen mediators,
such as prostaglandin D (POD2) tryptase and hista-
mine are released in the so-called early phase of the
allergic process. These meditors cause sneezing,
rhinorrhea and nasal congestion, which are the main
symptoms of allergic rhinitis when they interact with
neural elements, mucosal gland and blood vessels.
After a quiescent, period a second phase of the
allergic process occurs. In this so-called late phase
mediators are released again and symptoms recur, n-14
The effect of systemic steroids, such as prednisone,
reduce symptoms and mediator release in the late
phase of the process. They have little or no effect on
the early phase.
3,5 In contrast, topical steroids, such
as flunisolide, used in the nose reduce symptoms
and mediator release in the early phase as well in the
late phase of the allergic process in a study with
patients challenged with pollen antigens.a* The
corticosteroid, fluticasone propionate (FP) has po-
tent topical anti-inflammatory activity coupled with
low systemic activity. It has more than nine times the
anti-inflammatory activity of fluocinolone acetonide
and twice the activity of beclomethasone
dipropionate. 17a8
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The present study uses a nasal challenge model
developed by Naclerio et aLn to explore the role of
PAF and eicosanoids in the early and late phase of
the allergic process in patients with allergic rhinitis
against house dust mites. PAF could be involved in
respiratory allergies because PAF is a potent
eosinophil chemotactic factor. 19 However, to the
authors’ knowledge,, there are so far no available data
regarding in vivo PAF generation by human nasal
mucosa of patients allergic to house dust mites. In
this report, the effect of fluticasone propionate aque-
ous nasal spray, a new and potent corticosteroid, on
the levels of platelet activating factor (PAF),
leukotriene C4/D4/E (LTC4/D4/E4) and prostaglandin
D,. (PGD,) after nasal challenge with house dust mite
extract, is also described.
Materials and Methods
Patients: This study was performed in 24 patients.
There were 11 women and 13 men aged 21 to 50
years (mean, 34 years). All were characterized by a
history of perennial rhinitis, and by a positive skin
test to house dust mite extract. All patients showed
a skin reaction rated as at least one ’+’ sign to 0.3 to
3 Bu/ml extract, according to the standardized plus-
sign scoring system defined by Norman. ,. Six of the
24 patients were allergic to grass pollen or animal
dander as well. The nasal lavage experiments were
performed between January and August to minimize
exposure to house dust mites. The only patient with
a concomitant pollen allergy was tested outside the
pollen season. None of the patients allergic to ani-
mals had pets in their home. Antihistamines were
withdrawn 72 h before testing. The antihistamine
astemizole, topical corticosteroids, cromoglycate or
nedocromil were not used for 3 weeks before the
tests were performed. Oral corticosteroids had to be
withdrawn 2 months before the study. Patients who
developed a nasal infection during the 2-week
period before entering the study were excluded.
None had undergone immunotherapy previously.
The study was approved by the Medical Ethical
Committee of the University Hospital Rotterdam-
Dijkzigt and all patients gave written informed con-
sent.
Nasal challenge and lavage: After the positive skin
test the subjects entered the double blind placebo
controlled crossover phase of the study. Each under-
went two allergen challenges, performed after 2
weeks pretreatment with 200 l.tg fluticasone
propionate aqueous nasal spray (FPANS) (Glaxo,
GRD) or placebo spray twice daily. A 3-week wash-
out period separated the two challenges. Before
nasal challenge with house dust mite extract a nasal
lavage was performed four times to obtain baseline
mediator levels and to clear the nose from secretions.
To prevent nasal congestion caused by the allergen
challenges 0.250ml oxymetazoline (0.1%) was
sprayed into each nostril 5 min before the first chal-
lenge. Nasal lavage was performed as described by
Naclerio et al. and Gerth van Wijk et a/.1,2,22 Both
nostrils were washed with 5 ml saline, prewarmed to
37C. Lavage fluid was collected in plastic tubes that
were kept on ice. These lavage fluids were
centrifuged for 10 min at 400 xg and the super-
natants were stored at-70C until detection of PAF
or eicosanoids. To obtain a control challenge,
0.125ml phosphate buffered saline (PBS) was
sprayed in each nostril and a nasal lavage was per-
formed. For allergen challenge 0.125 ml allergen
extract was sprayed in each nostril and after 10 min
thereafter a nasal lavage was performed. Allergen
doses of 100, 1 000, 10 000 Biological Units (Bu)/ml
(extract of Dermatophagoides pteronyssinus; ALK,
Groningen, The Netherlands) were administered.
From 30 min up to 9.5 h after this challenge the nasal
fluid was obtained every hour by washing the nose
with saline. Allergen-induced secretion collected
before nasal lavage was not used for analysis. From
the series of lavages the levels of PAF, LTC4/D4/E
and PGD2, as indicators of mediator release, were
measured at the following time points: baseline (t
_1/), allergen provocation with 10 000 Bu/ml (t 0),
3.5 and 7.5 h. These time points were chosen based
on recently described studies,1,22 in which it was
shown that between 3 and 10 h after antigen chal-
lenge the late phase reaction occurred.
Symptom score: Symptoms were scored according to
a scoring system described by Lebel et al. 23 These
symptoms were observed in order to study the cor-
relation between these clinical symptoms and the
inflammatory mediators. The score was compiled
before each lavage and after PBS and each allergen
insufflation.
Mediator assays: The levels of PAF, LTC4/D4/E4 and
PGD,. were measured by Scintillation Proximity Assay
(SPA), BiotrakR and Radioimmunoassay (RIA) respec-
tively (Amersham, UK). The limits of sensitivity of
the assays were approximately 20, 3.1 and 0.75 pg/
100 l.tl respectively. Cross-reactivity (50% B/B0 dis-
placement) of: PAF assay, 1-hexadecyl-2-acetyl GPC-
PAF(C16:0) (100%), 1-octadecyl-2-acetyl GPC-
PAF(C18:0) (40%), racPAF (29%), 1-hexadecyl-2-1yso
GPC-Lyso-PAF(C16:0) (< 0.01%); LTC4/D4/E assay:
LTC (100%), LTD (100%), LTE (70%), LTB (0.4%)
and prostaglandins (< 0.006%); PGD2 assay, PGD2
(100%), PGJ2 (7%), TxB (0.3%), PGF, (0.04%) and
other prostaglandins (< 0.02%0).
Statistical analysis: Statistical analysis was performed
with the Friedman two-way ANOVA followed by the
Wilcoxon matched-pairs signed-ranks test. The
Kruskal-Wallis rank test was used for correlations.
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For testing equality of the carry-over effect, within-
patient totals over the two treatment periods are
used. There is said to be no significant carry-over
effect if the means of these within-patient totals do
not significantly differ between the two treatment-
order groups. For this test a p-value < 10% is consid-
ered significant.
Results
Nasal mediator release: The levels of the inflamma-
tory mediators, PAF, LTC4/D4/E4, and PGD,., in nasal
washings from allergic patients to house dust mites
with and without fluticasone propionate aqueous
nasal spray (FPANS) are presented in Table 1. No
significant carry-over effect was observed. The base-
line levels of the placebo group and FPANS group
respectively are: PAF, 907 + 177 (range 147-3172)
and 780 + 316 (range 95-7272) pg/ml; .LTC4/D4/E4,
112 + 10 (range 37-233) and 106 + 9 (range 10-209)
pg/ml and PGD2, 94 + 26 (range 21-592) and 92 + 30
(range 3-734) pg/ml. Because these baseline levels
are in a large range, the levels are recalculated in
percent change to baseline.
Nasal challenge with house dust mite extract
caused an immediate influx of these inflammatory
mediators. After allergen provocation the levels of
the mediators increased in the nasal fluids of placebo
treated patients (x-fold increase to baseline: PAF, 15;
LTC4/D4/E4: 12; and PGD,., 1.5). In fluids of patients
treated with FPANS these levels tended to decrease
(x-fold increase to baseline: PAF, 6; LTC4/D4/E4, 4;
and PGD2, 1.1). p Value between the placebo and
FPANS group after the primary trigger initiated after
challenge with 10 000 Bu/ml house dust mite extract
of PAF, 0.2124; ITC4/D4/E4, 0.1618; and PGD,., 0.2227.
At 3.5 and 7.5 h after this challenge a significant
decrease of PAF, LTC4/D4/E and PGD,. was observed
in both groups compared with the value at the time
point of allergen provocation with 10 000 Bu/ml
house dust mite extract. The p values of the placebo
group and the FPANS group at 3.5 h are respectively:
PAF, 0.0004 and 0.0010; LTC4/LTD4/LTE4, 0.0003 and
0.0003; PGD,., 0.0126 and 0.0116. At 7.5 hthe pvalues
of the placebo group and the FPANS group are
respectively: PAF, 0.0116 and 0.0184; LTC4/D4/E4:
0.0300 and 0.0025; PGD2, 0.0023 and 0.0936.
Symptom score. The means (+S.E.M.) of the symptom
score are shown in Fig. 1. Because a significant carry-
over effect was observed, only the results of the first
treatment period was used. A significant increase is
observed immediatelyafter the challenge with house
dust mite extract in the placebo and FPANS group. At
3.5 and 7.5 h after this challenge a significant de-
crease of the symptom score is observed as com-
pared to the level at the time point of the challenge
in both groups (p 0.001). The symptom score of
patients treated with FPANS is decreased in compari-
son to the placebo group.
Correlation between inflammatory mediators and
symptom score. A significant correlation (p < 0.05)




B HDM 10000 3.5 7.5
FIG. 1. Symptom score at the following time points: baseline (B), allergen
provocation with 10 000 Bu/ml house dust mite extract (t 0), 3.5 and 7.5 h
(late phase) of allergic patients treated with or without FPANS.. Values are
expressed mean S.E.M. Statistical significant difference to the HDM
10 000 is shown by an asterisk. (p _< 0.05). Statistical significant difference
to the baseline is shown by a double asterisk (p _< 0.05). Key: [], placebo;
I, fluticasone propionate aqueous nasal spray.
Table 1. Platelet activating factor (PAF), leukotriene CJDJE, (LTCJDJE,) and prostaglandin D (PGD2)
production in nasal lavages
HDM 10 000 Bu/ml 3.5 h 7,5 h
Placebo FPANS Placebo FPANS Placebo FPANS
PAF 1490 +/- 479 554 +/- 283 5 +/- 19* 29 +/- 37* 19 +/- 20* +/- 28*
LTCJD,/E, 1115 +/- 518 355 +/- 190 4 +/- 9* 21 +/- 7* 6 +/- 7* 9 +/- 9*
PGD 50+/-26 8+/- 16 -42+/- 11" -42+/- 10" -39+/-8* -29+/- 12
Results were obtained at the following time points: allergen provocation with 10 000 Bu/ml house dust mite
(HDM) extract (t 0), 3.5 and 7.5 h (late phase) of allergic patients treated with placebo or with fluticasone
propionate aqueous spray (FPANS). Because of scattered individual data values are expressed as
percent change of baseline +/- S.E.M. Statistical significant decrease to the HDM 10 000 is shewn with an
asterisk, according to the Wilcoxon matched-pairs signed-ranks test (p _< 0.05).
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Bu/ml house dust mite extract between: (1) the
release of LTC4/D4/E and POD in the placebo group
(correlation coefficient, c 0.656) and in the FPANS
group (c 0.776); (2) the release of PAF and LTC4/
D4/E in the placebo group (c 0.719) and in the
FPANS group (c 0.990); (3) the release of PAF and
PGD after the administration of placebo (c 0.466)
or FPANS (c 0.740); (4) the release of LTC4/D4/E
and symptom score in the placebo group (c 0.547)
and in the FPANS group (c= 0.545); and (5) the
release of PAF and symptom score of the FPANS
group (c 0.598).
Discussion
Lavage of the nasal mucosa appears to be a con-
venient model for measuring inflammatory mediator
release during an allergic reaction to the house dust
mite. In agreement with other investigators it was
found that within a few minutes of exposure to an
allergen leukotrienes and prostaglandins can be
measured in nasal washings. 11’24-28 This is the first
study in which PAF could be measured in nasal
lavages in detectable amounts seen within a few
minutes after nasal provocation with house dust mite
extract. Other investigators found lyso-PAF but al-
most no PAF by bioassay in nasal washings after
nasal challenge of patients with a pollen allergy.29,3
In vitro studies have demonstrated that PAF is
released by alveolar macrophages,31 eosinophils,32
monocytes and endothelial cells34,35 and platelets.36 It
has now been demonstrated that PAF is present in
nasal lavages of patients with house dust mite al-
lergy; however, the origin of PAF is uncertain. In the
early phase of the allergic process IgE crosslinks by
antigen challenge on mast cells and basophils, which
release primary mediators. After a quiescent period a
.late phase allergic reaction occurs, in which
eosinophils and macrophages are involved, releasing
secondary mediators.1>4 It has been shown that PAF
is released during the early phase reaction as primary
mediator and not as a secondary mediator. The
present study also shows that PGD,. is released only
during the early phase of the allergic process as a
primary mediator. This is in agreement with other
investigators, who found that PGD is produced by
mastcells. 37,38 Sulfidopeptide-leukotrienes are known
to be released by eosinophils39-41 and macro-
phages,4-44 which indicated that LTC4/LTD4/LTE4 are
secondary mediators. However, these sulfido-
peptide-leukotrienes were released only during the
early phase reaction and not during the late phase
reaction, which indicated that these sulfidopeptide-
leukotrienes are also primary mediators. The genera-
tion of the mediators PAF, LTC4/D4/E4 and PGD2,
reached baseline levels after 3.5 h. During the late
phase reaction symptoms partially recurred, but sur-
prisingly PAF, LTC4/D4/E and PGD2 were not re-
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leased again. These symptoms should be due to
other mediators. Furthermore .it was clearly demon-
strated that the release of PAF, LTC4/D4/E and PGD2
correlated with each other immediately at the time
point of the nasal challenge with house dust mite
extract. Previous reports of studies with patients
allergic to grass pollen and ragweed described a
correlation between LTC4/D4/E and POD2 .23,45 We
also found a significant correlation between the re-
lease of LTC4/D4/E4 and PAF with the symptom score
at the time point of challenge, but not between the
release of PGD2 and the symptom score. However,
Lebel et al."3 who studied patients with a grass pollen
allergy observed that the release of PGD was well
correlated with the symptom score.
In this study pretreatment of the patients with
FPANS for 2 weeks twice daily greatly reduced the
development of symptoms. In a study performed
with 17 atopic patients, during a 2 week pretreatment
with FPANS 200 l.tg/day the immediate increase in
nasal airway resistance was not inhibited.46 In an-
other study the dose of ragweed pollen required to
produce a standardised response was unchanged
after 4 weeks of treatment with FPANS 200 l.tg/day in
49 patients during the ragweed season.47 However,
FPANS improved the symptom score after 2 and 4
weeks of treatment in 24 patients with seasonal
allergic rhinitis after nasal challenge with allergen.48
It has been suggested that the number of
eosinophils and basophilic cells (basophils and mast
cells) increase following allergen challenge and that
this factor is responsible for the initiation of the
allergic vascular response.49,5 Treatment with FPANS
50 to 800 t.tg/day administered for 2 weeks to 6
months was associated with a significant decrease in
the number of nasal eosinophils, basophils and
neutrophils compared with placebo patients with
seasonal allergic rhinitis.5 It has been proposed that
FPANS may act by preventing activation of several
cells and subsequent release of inflammatory media-
tors. 30
The present findings indicate that FPANS
reduces not only the allergen induced symptoms
(ratio placebo:FPANS, 1.68) but also tended to
reduce the release of PAF (ratio placebo:FPANS,
2.69), LTC4/D4/E4 (ratio placebo:FPANS, 3.14)
and PGD2 (ratio placebo:FPANS, 6.25) after the
primary trigger initiated after challenge with
10 000 Bu/ml house dust mite extract at the time
point of challenge.
In conclusion, the results indicate that the inflam-
matory mediators platelet activating factor,
leukotriene C4/D4/E4 and prostaglandin D2 can be
used as markers of allergic reactions to house dust
mites and that fluticasone propionate aqueous nasal
spray counteracts the release of mediators of inflam-
mation, correlated with beneficial effects on clinical
symptoms in this type of allergic reaction.Fluticasone propionate aqueous nasal spray and mediators
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